Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
|Articles|January 21, 2022
Pharmacy Clinical Pearl of the Day: Glioblastoma
Author(s)Saro Arakelians, PharmD
Glioblastoma can be very difficult to treat and a cure is often not possible.
Advertisement
Clinical Pearl of the Day: Glioblastoma
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord.
Insight:
- Glioblastoma forms from cells called astrocytes that support nerve cells.
- Glioblastoma can occur at any age but tends to occur more often in older adults. It can cause worsening headaches, nausea, vomiting, and seizures.
- Glioblastoma, also known as glioblastoma multiforme, can be very difficult to treat and a cure is often not possible.
- Treatments may slow progression of the cancer and reduce signs and symptoms.
- Diagnosis is done by the use of imaging studies, neurological exams, and biopsy.
- Treatment includes surgery, radiation therapy, chemotherapy, tumor treating fields therapy, and targeted drug therapy.
Sources:
Advertisement
Related to this article
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
ASRA’s cancer pain programming highlights opportunities for pharmacists to individualize opioid therapy, improve medication transitions, and connect patients with evidence-based complementary care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Glucose Monitoring: Timing Makes Every Reading Count
3
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5